Company Overview of VCN Biosciences SL
VCN Biosciences SL develops therapeutic agents for the treatment tumors. It develops VCN-01, a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase that degrades a structural element of tumor extracellular matrix; and treatments for refractory tumors, such as pancreatic adenocarcinomas. VCN Biosciences SL was founded in 2009 and is based in Barcelona, Spain. VCN Biosciences SL operates as a subsidiary of Gri-Cel, S.A.
Av. de la Generalitat 152
Sant Cugat del Vallès
Founded in 2009
34 93 571 23 59
34 93 571 21 29
Key Executives for VCN Biosciences SL
VCN Biosciences SL Key Developments
Similar Private Companies By Industry
|ABAC Therapeutics SA||Europe|
|Adan Medical Innovation, S.L.||Europe|
|Advanced In Vitro Cell Technologies S.A.||Europe|
|Advanced Marker Discovery, S.L.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact VCN Biosciences SL, please visit www.vcnbiosciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.